COMMUNIQUÉS West-GlobeNewswire

CARBIOS se réjouit de l'autorisation du régime d'aide d'État "Économie circulaire" par la Commission européenne

06/02/2025 - 18:30

Une étape significative pour le versement des subventions validées par la Région Grand Est et l’ADEME, d’un montant total de 42,5M€, destinées à la construction de l’usine de biorecyclage de Longlaville CARBIOS [...]

CARBIOS is pleased that the European Commission has authorised the ‘Circular Economy’ State aid scheme

06/02/2025 - 18:30

A significant step towards the payment to CARBIOS of grant subsidies validated by ADEME and the Grand Est Region, totalling €42.5m, for the construction of the CARBIOS Longlaville biorecycling plant in France CARBIOS [...]

Lytus Technologies Expands HealthTech Initiatives and Strengthens Growth Trajectory

06/02/2025 - 18:48

Lytus Healthcare launched to transform patient care in India Company positioned to build on revenue growth momentum Secures strategic financing to fuel next-generation technology expansion Mumbai, India, Feb. 06, 2025 ( [...]

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

06/02/2025 - 20:07

Raised approximately $2.118 million in gross proceeds since the beginning of 2025 WASHINGTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical [...]

MannKind to Present at Upcoming Investor Conferences

06/02/2025 - 22:05

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products [...]

BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

06/02/2025 - 22:05

LOUISVILLE, Ky., Feb. 06, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its fourth quarter and full year 2024 [...]

Senseonics Completes CE Mark Submission for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor

06/02/2025 - 22:05

GERMANTOWN, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

06/02/2025 - 22:05

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06/02/2025 - 22:05

SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]

Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

06/02/2025 - 22:05

REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of [...]

PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli

06/02/2025 - 22:06

TORONTO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]

LifeStance to Host Fourth Quarter and Full Year 2024 Earnings Conference Call on February 27, 2025

06/02/2025 - 22:10

SCOTTSDALE, Ariz., Feb. 06, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its fourth quarter and full year 2024 [...]

GENFIT présente le design de ses prochains essais cliniques et rappelle les grandes étapes de développement et données cliniques attendues en 2025

06/02/2025 - 22:10

Lancements de 2 nouveaux essais cliniques dans l’ACLF prévus au premier trimestre 2025 Résultats de 3 essais cliniques attendus dans l’ACLF d’ici fin 2025, dont ceux de l’essai de Phase 2 UNVEIL-IT® en cours Données de [...]

GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

06/02/2025 - 22:10

2 new ACLF clinical trials expected to initiate in 1Q25 3 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trial Data of on-going Phase 1b also expected by [...]

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

06/02/2025 - 22:15

Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on [...]

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

06/02/2025 - 22:15

Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on [...]

Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

06/02/2025 - 22:15

PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]

Neuronetics Announces Launch of Underwritten Public Offering of Common Stock

06/02/2025 - 22:23

MALVERN, Pa., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced that it has commenced an underwritten public offering of its common stock. In connection with the offering [...]

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

06/02/2025 - 22:30

NOVATO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and [...]